Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and poop samples: the future of heart attack prevention?

NCT ID NCT07471763

Knowledge-focused Sponsor: Fujian Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will follow 6000 people with heart disease or recent heart attacks for years. Researchers will collect blood, urine, and stool samples, plus medical data, to build a huge database. They hope artificial intelligence can find new ways to predict, diagnose, and treat heart attacks more precisely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better tools for predicting, diagnosing, and managing heart attacks using artificial intelligence and biological data.
What could go wrong
This is an observational study, not a treatment trial. It may not produce immediate clinical changes, and results depend on data quality and long-term follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 to 74 years will be enrolled into two cohorts: a high-risk population cohort including individuals with stable angina or unstable angina, and a confirmed acute myocardial infarction cohort including patients diagnosed according to the Fourth Universal Definition of Myocardial Infarction. All participants must be able to provide informed consent and complete baseline assessment, biospecimen collection, and longitudinal follow-up.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 to 74 years Diagnosed with stable angina, unstable angina, or acute myocardial infarction For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction Willing to participate and able to provide written informed consent Able to complete baseline assessment, biospecimen collection, and long-term follow-up Exclusion Criteria: End-stage malignant tumor with expected survival of less than 1 year Severe hepatic or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m² or Child-Pugh class C) Active autoimmune disease or long-term use of immunosuppressive agents Pregnant or breastfeeding women Inability to provide informed consent or severe cognitive impairment Previous participation in another clinical study that may conflict with this project Any other condition considered by the investigators to make participation inappropriate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction Angina, Stable intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI) Stable angina Unstable angina

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuzhou University Affiliated Provincial Hospital

    Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.